| D007942 |
Leukemia, Experimental |
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. |
Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal |
|
| D008748 |
Methylcholanthrene |
A carcinogen that is often used in experimental cancer studies. |
20-Methylcholanthrene,3-Methylcholanthrene,20 Methylcholanthrene,3 Methylcholanthrene |
|
| D008861 |
Microsomes |
Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (Glick, Glossary of Biochemistry and Molecular Biology, 1990; from Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) |
Microsome |
|
| D010088 |
Oxidoreductases |
The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) |
Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase |
|
| D010634 |
Phenobarbital |
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. |
Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital |
|
| D011292 |
Premedication |
Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION. |
Premedications |
|
| D011335 |
Proadifen |
An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity. |
Propyladiphenin,Diethylaminoethyldiphenylpropyl Acetate,Proadifen Hydrochloride,SK&F-525-A,SK-525A,SKF-525-A,SKF-525A,Acetate, Diethylaminoethyldiphenylpropyl,Hydrochloride, Proadifen,SK 525A,SK&F 525 A,SK&F525A,SK525A,SKF 525 A,SKF525A |
|
| D011925 |
Rauscher Virus |
A strain of MURINE LEUKEMIA VIRUS associated with mouse tumors similar to those caused by the FRIEND MURINE LEUKEMIA VIRUS. It is a replication-competent murine leukemia virus. It can act as a helper virus when complexing with a defective transforming component, RAUSCHER SPLEEN FOCUS-FORMING VIRUS. |
Rauscher leukemia virus,Rauscher leukemia viruses,Virus, Rauscher,leukemia viruses, Rauscher |
|
| D004336 |
Drug Antagonism |
Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy. |
Antagonism, Drug,Antagonisms, Drug,Drug Antagonisms |
|
| D004357 |
Drug Synergism |
The action of a drug in promoting or enhancing the effectiveness of another drug. |
Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug |
|